文献速递泌尿男性生殖肿瘤

在激素初治前列腺癌中添加塞来昔布联合或不联合唑来膦酸:自适应、多臂、多阶段平台随机对照试验的长期生存结果

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
PubMed 文献 · J Clin Oncol · 2017-03-13

STAMPEDE平台试验入组1245例高危局部晚期或转移性前列腺癌患者,随机分配至标准治疗(SOC)、SOC+塞来昔布(Cel)或SOC+唑来膦酸(ZA)+Cel。中位随访69个月,SOC+ZA+Cel组转移性疾病亚组分析显示风险比0.78(95%CI 0.62-0.98;P=0.033)。总体未显示塞来昔布改善生存的证据。

要点

  • SOC+Cel组调整HR 0.98(95%CI 0.80-1.20;P=0.847),中位生存70个月,与SOC无显著差异。
  • SOC+ZA+Cel组调整HR 0.86(95%CI 0.70-1.05;P=0.130),中位生存76个月,未达统计学显著。
  • 转移性疾病亚组中SOC+ZA+Cel的HR 0.78(95%CI 0.62-0.98;P=0.033),为未来研究提供假设。

核心结论

  • 总体数据未显示塞来昔布改善生存的证据。
  • 预先计划的亚组分析为未来研究提供假设。

研究设计与样本

  • STAMPEDE是一项采用多臂、多阶段、平台设计的随机对照试验。
  • 入组正在开始长期激素治疗的高危局部晚期或转移性前列腺癌男性。
  • 共1245例男性于2005年10月至2011年4月随机分配(2:1:1)至SOC、SOC+Cel或SOC+ZA+Cel。
  • 主要结局为全因死亡,采用Cox比例风险模型和校正分层因素的灵活参数模型分析。

主要发现

  • 中位年龄65岁;61%转移性,14% N+/X M0,25% N0M0;94%新诊断;中位前列腺特异性抗原66 ng/mL。
  • 中位随访69个月;仅SOC组死亡303例(83%为前列腺癌),中位生存66个月。
  • 3至5级不良事件:仅SOC组36%,SOC+Cel组33%,SOC+ZA+Cel组32%。
  • 与SOC相比,SOC+Cel调整HR 0.98(95%CI 0.80-1.20;P=0.847;中位生存70个月)。
  • 与SOC相比,SOC+ZA+Cel调整HR 0.86(95%CI 0.70-1.05;P=0.130;中位生存76个月)。

关键数值与推荐

  • SOC为持续激素治疗(转移性)或≥2年(非转移性);无转移男性鼓励前列腺(±盆腔淋巴结)放疗。
  • 塞来昔布400 mg每日两次,服用1年。
  • 唑来膦酸4 mg每3周一次共6周期,随后每4周一次共2年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 两个含塞来昔布的对比因中期分析基于无失败生存而提前停止入组。
  • 预先计划的亚组分析结果仅为假设,需未来研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally advanced or metastatic prostate cancer who were initiating long-term hormone therapy. We report survival data for two celecoxib (Cel)-containing comparisons, which stopped accrual early at interim analysis on the basis of failure-free survival. Patients and Methods Standard of care (SOC) was hormone therapy continuously (metastatic) or for ≥ 2 years (nonmetastatic); prostate (± pelvic node) radiotherapy was encouraged for men without metastases. Cel 400 mg was administered twice a day for 1 year. Zoledronic acid (ZA) 4 mg was administered for six 3-weekly cycles, then 4-weekly for 2 years. Stratified random assignment allocated patients 2:1:1 to SOC (control), SOC + Cel, or SOC + ZA + Cel. The primary outcome measure was all-cause mortality. Results were analyzed with Cox proportional hazards and flexible parametric models adjusted for stratification factors. Results A total of 1,245 men were randomly assigned (Oct 2005 to April 2011). Groups were balanced: median age, 65 years; 61% metastatic, 14% N+/X M0, 25% N0M0; 94% newly diagnosed; median prostate-specific antigen, 66 ng/mL. Median follow-up was 69 months. Grade 3 to 5 adverse events were seen in 36% SOC-only, 33% SOC + Cel, and 32% SOC + ZA + Cel patients. There were 303 control arm deaths (83% prostate cancer), and median survival was 66 months. Compared with SOC, the adjusted hazard ratio was 0.98 (95% CI, 0.80 to 1.20; P = .847; median survival, 70 months) for SOC + Cel and 0.86 (95% CI, 0.70 to 1.05; P =.130; median survival, 76 months) for SOC + ZA + Cel. Preplanned subgroup analyses in men with metastatic disease showed a hazard ratio of 0.78 (95% CI, 0.62 to 0.98; P = .033) for SOC + ZA + Cel. Conclusion These data show no overall evidence of improved survival with Cel. Preplanned subgroup analyses provide hypotheses for future studies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Mason MD, Clarke NW, James ND, et al. Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. J Clin Oncol. 2017. PMID: 28300506. doi:10.1200/JCO.2016.69.0677

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。